Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18547998 | 0.85 | HTR1F (0.58) | HTR1FKMT2ASMN1; SMN2 | |
| SCHEMBL20030849 | 0.84 | USP30 (0.38) | HTR1FALDH1A1DGAT1KMT2AMEN1 | |
| SCHEMBL1173693 | 0.82 | DGAT1 (0.44) | HTR1FALDH1A1DGAT1KMT2AMEN1 | |
| SCHEMBL873620 | 0.80 | ALDH1A1 (0.42) | HTR1FALDH1A1DGAT1KMT2AMEN1 | |
| SCHEMBL20030977 | 0.79 | USP30 (0.57) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL24147773 | 0.78 | DGAT1 (0.41) | HTR1FALDH1A1DGAT1KMT2AMEN1 | |
| SCHEMBL18547956 | 0.77 | HTR3E (0.44) | HTR1FDGAT1KMT2AMEN1LMNA | |
| SCHEMBL18554588 | 0.75 | HSD11B1 (0.48) | HTR1FALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4190126 | 0.74 | MGLL (0.51) | ALDH1A1KMT2AMEN1GAALMNA | |
| SCHEMBL17495365 | 0.72 | USP30 (0.50) | KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | HTR1F 3274/4885ALDH1A1 321/4885DGAT1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.